June 2011. Volume 7. Number 2

Intravitreal bevacizumab is effective as treatment of infants with severe retinopathy of prematurity

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603-15.
Reviewers: González de Dios J1, Molina Arias M2.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2Servicio de Gastroenterología y Nutrición. Hospital Infantil Universitario La Paz. Madrid. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 07/04/2011
Acceptance date: 08/04/2011
Publication date: 13/04/2011

Abstract

Author's conclusions: intravitreal bevacizumab, as compared with conventional laser therapy, showed a significant benefit in infants with stage 3+ retinopathy of prematurity with zone I disease, but not zone II disease.

Reviewers' conclusions: intravitreal bevacizumab, which has showed efficacy and a simple way of administration, could became the first choice for treatment in infants with stage 3+ retinopathy of prematurity with zone I disease. Additional research is needed to determine criteria for its use in other stages of retinopathy and to asses its clinical safety.

How to cite this article

González de Dios J, Molina Arias M. El bevacizumab intravítreo es eficaz para el tratamiento de la retinopatía de la prematuridad grave. Evid Pediatr. 2011;7:36.

AVC | Critically appraised articles

Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603-15.
Reviewers: González de Dios J1, Molina Arias M2.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2Servicio de Gastroenterología y Nutrición. Hospital Infantil Universitario La Paz. Madrid. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 07/04/2011
Acceptance date: 08/04/2011
Publication date: 13/04/2011

How to cite this article

González de Dios J, Molina Arias M. El bevacizumab intravítreo es eficaz para el tratamiento de la retinopatía de la prematuridad grave. Evid Pediatr. 2011;7:36.

References

  1. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 1988;106:471-9.
  2. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684-94.
  3. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol. 2010;21:218-26.
  4. Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chevez-Barrios P. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol. 2008;126:1161-3.
  5. O'Keefe M, Lanigan B, Long VW. Outcome of zone 1 retinopathy of prematurity. Acta Ophthalmol Scand. 2003;81:614-6.
13/04/2011

Linked Comment